Solar elastosis correlates with high tumor mutation burden and better 5-year disease-specific survival in patients with stage II/III melanoma

Objective: To evaluate the relation between solar elastosis and tumor mutation burden (TMB) in a large clinically annotated cohort of stage II and III melanoma patients. Methods: Primary cutaneous melanomas from 469 AJCC (8th edition) stage II and III patients with clinical annotation including outc...

Full description

Saved in:
Bibliographic Details
Main Authors: Cecilia Lezcano, Li Luo, Ronglai Shen, Irene Orlow, Nancy E. Thomas, Marianne Berwick, Klaus J. Busam
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:EJC Skin Cancer
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2772611824002623
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850061648067297280
author Cecilia Lezcano
Li Luo
Ronglai Shen
Irene Orlow
Nancy E. Thomas
Marianne Berwick
Klaus J. Busam
author_facet Cecilia Lezcano
Li Luo
Ronglai Shen
Irene Orlow
Nancy E. Thomas
Marianne Berwick
Klaus J. Busam
author_sort Cecilia Lezcano
collection DOAJ
description Objective: To evaluate the relation between solar elastosis and tumor mutation burden (TMB) in a large clinically annotated cohort of stage II and III melanoma patients. Methods: Primary cutaneous melanomas from 469 AJCC (8th edition) stage II and III patients with clinical annotation including outcome at 5 years of diagnosis were histopathologically evaluated for solar elastosis. Next-generation sequencing assay MSK-IMPACTTM was employed to determine TMB. Analysis by Fisher’s exact test, chi-square, and Kruskal-Wallis were performed, as well as uni- and multivariate logistic regression. Results: Tumors stratified by low and high TMB showed marked and statistically significant differences in presence and extent of associated solar elastosis. Lower risk patient stage (II versus III by AJCC 8th edition) as well as better 5-year melanomaspecific survival (as binary variable of controls-survivors versus cases-dead of disease at 5 years of diagnosis) were associated with severe solar elastosis. On univariate and multivariate logistic regression models, severe solar elastosis predicted significantly decreased odds of dying of melanoma within 5 years of diagnosis (OR 0.60, 95 % CI 0.39–0.89; and OR 0.42, 95 % CI 0.20–0.83, respectively; both p<0.05) Conclusion: The association of solar elastosis to TMB and 5-year melanoma specific survival points to its potential as a biomarker of clinical relevance that can be assessed by routine histopathology.
format Article
id doaj-art-fa9184bccc8b4c7fbdb383182b3fc673
institution DOAJ
issn 2772-6118
language English
publishDate 2024-12-01
publisher Elsevier
record_format Article
series EJC Skin Cancer
spelling doaj-art-fa9184bccc8b4c7fbdb383182b3fc6732025-08-20T02:50:09ZengElsevierEJC Skin Cancer2772-61182024-12-01210027410.1016/j.ejcskn.2024.100274Solar elastosis correlates with high tumor mutation burden and better 5-year disease-specific survival in patients with stage II/III melanomaCecilia Lezcano0Li Luo1Ronglai Shen2Irene Orlow3Nancy E. Thomas4Marianne Berwick5Klaus J. Busam6Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Correspondence to: Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.Department of Internal Medicine and the University of New Mexico Comprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USADepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USADepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USADepartment of Dermatology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USADepartment of Internal Medicine and the University of New Mexico Comprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USADepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAObjective: To evaluate the relation between solar elastosis and tumor mutation burden (TMB) in a large clinically annotated cohort of stage II and III melanoma patients. Methods: Primary cutaneous melanomas from 469 AJCC (8th edition) stage II and III patients with clinical annotation including outcome at 5 years of diagnosis were histopathologically evaluated for solar elastosis. Next-generation sequencing assay MSK-IMPACTTM was employed to determine TMB. Analysis by Fisher’s exact test, chi-square, and Kruskal-Wallis were performed, as well as uni- and multivariate logistic regression. Results: Tumors stratified by low and high TMB showed marked and statistically significant differences in presence and extent of associated solar elastosis. Lower risk patient stage (II versus III by AJCC 8th edition) as well as better 5-year melanomaspecific survival (as binary variable of controls-survivors versus cases-dead of disease at 5 years of diagnosis) were associated with severe solar elastosis. On univariate and multivariate logistic regression models, severe solar elastosis predicted significantly decreased odds of dying of melanoma within 5 years of diagnosis (OR 0.60, 95 % CI 0.39–0.89; and OR 0.42, 95 % CI 0.20–0.83, respectively; both p<0.05) Conclusion: The association of solar elastosis to TMB and 5-year melanoma specific survival points to its potential as a biomarker of clinical relevance that can be assessed by routine histopathology.http://www.sciencedirect.com/science/article/pii/S2772611824002623MelanomaSolar elastosisTumor mutation burden
spellingShingle Cecilia Lezcano
Li Luo
Ronglai Shen
Irene Orlow
Nancy E. Thomas
Marianne Berwick
Klaus J. Busam
Solar elastosis correlates with high tumor mutation burden and better 5-year disease-specific survival in patients with stage II/III melanoma
EJC Skin Cancer
Melanoma
Solar elastosis
Tumor mutation burden
title Solar elastosis correlates with high tumor mutation burden and better 5-year disease-specific survival in patients with stage II/III melanoma
title_full Solar elastosis correlates with high tumor mutation burden and better 5-year disease-specific survival in patients with stage II/III melanoma
title_fullStr Solar elastosis correlates with high tumor mutation burden and better 5-year disease-specific survival in patients with stage II/III melanoma
title_full_unstemmed Solar elastosis correlates with high tumor mutation burden and better 5-year disease-specific survival in patients with stage II/III melanoma
title_short Solar elastosis correlates with high tumor mutation burden and better 5-year disease-specific survival in patients with stage II/III melanoma
title_sort solar elastosis correlates with high tumor mutation burden and better 5 year disease specific survival in patients with stage ii iii melanoma
topic Melanoma
Solar elastosis
Tumor mutation burden
url http://www.sciencedirect.com/science/article/pii/S2772611824002623
work_keys_str_mv AT cecilialezcano solarelastosiscorrelateswithhightumormutationburdenandbetter5yeardiseasespecificsurvivalinpatientswithstageiiiiimelanoma
AT liluo solarelastosiscorrelateswithhightumormutationburdenandbetter5yeardiseasespecificsurvivalinpatientswithstageiiiiimelanoma
AT ronglaishen solarelastosiscorrelateswithhightumormutationburdenandbetter5yeardiseasespecificsurvivalinpatientswithstageiiiiimelanoma
AT ireneorlow solarelastosiscorrelateswithhightumormutationburdenandbetter5yeardiseasespecificsurvivalinpatientswithstageiiiiimelanoma
AT nancyethomas solarelastosiscorrelateswithhightumormutationburdenandbetter5yeardiseasespecificsurvivalinpatientswithstageiiiiimelanoma
AT marianneberwick solarelastosiscorrelateswithhightumormutationburdenandbetter5yeardiseasespecificsurvivalinpatientswithstageiiiiimelanoma
AT klausjbusam solarelastosiscorrelateswithhightumormutationburdenandbetter5yeardiseasespecificsurvivalinpatientswithstageiiiiimelanoma